Background
Although data on the incidence of heart failure are limited, it appears to range from one to five cases per 1,000 population each year in the general population, increasing steeply with age to more than 30 cases per 1,000 population each year among people aged 75 years or older. 1 Considerably more prevalence data are available, although there is a wide variation due to the large differences in the methods used. Generalpopulation prevalence ranges between three and 20 individuals per 1,000, increasing to between 80 and 160 individuals per 1,000 among those aged 75 years or older. These data consistently demonstrate the pronounced influence of age, such as the doubling-by-decade effect on incidence recorded in the Framingham study. 2 In this study only 25% of men and 38% of women were alive five years after the diagnosis of heart failure. Hospital series, which include more severe cases, show a one-year mortality of 30-50%. In contrast, annual mortality for patients with chronic stable heart failure is about 10%. Heart failure mortality data are comparable to those for the worst forms of malignant disease, although this is not a generally recognised fact.
During the past 20-30 years, coronary heart disease mortality rates have declined steadily in western countries. Despite this trend, which has been attributed to a combination of primary preventative measures and improved disease management, heart failure remains an important and increasing public-health problem. Admissions to hospital because of heart failure seem to be increasing, due partly to the ageing of populations and greater survival of patients with coronary heart disease. Substantial healthcare expenditure is required for heart failure management, of which hospital-related costs account for the largest proportion.
There is an apparent disparity in the relative importance of hypertension and coronary heart disease as causes of heart failure suggested from cohort studies and from current clinical experience. 3 In the Framingham cohort study, for example, most of the population-attributable risk for heart failure was due to hypertension. Although risk factors were well characterised in this study, objective evidence of left-ventricular dilatation and systolic dysfunction was not a requirement for the diagnosis of heart failure. This lack of specificity may therefore have resulted in the inclusion of patients with dyspnoea due to myocardial ischaemia or diastolic dysfunction. Such patients would generally be excluded from clinical trials of heart failure treatment, which mainly select patients with left-ventricular systolic dysfunction of ischaemic aetiology. Many clinical trial patients with heart failure attributed to coronary disease may, however, have had important long-term hypertension, perhaps undetected or historically obscure, that eventually contributed to coronary heart disease and consequent heart failure. Alternatively, in elderly
patients, hypertension and progressive leftventricular hypertrophy may precede primary diastolic dysfunction; such patients would generally be excluded from consideration for clinical trials although the importance of diastolic heart failure is becoming increasingly recognised. Diabetes mellitus is an important risk factor for heart failure that potentially contributes to coronary heart disease or directly to myocardial disease. Obesity may confound diagnosis and be a contributory cause.
Blockade of the renin-angiotensin system began as a way of studying the pathogenesis of cardiovascular disease with specific pharmacological probes. Oral activity, achieved by shortening the original peptide structures, transformed the probes into therapeutic agents, the angiotensin-converting enzyme (ACE) inhibitors. However, ACE is a non-specific target for blocking the renin-angiotensin enzymatic cascade.
The largest proportion of trials in patients with heart failure have involved ACE inhibitors. The Captopril-Multicenter Study started the present era of heart failure trials and showed for the first time in a rigorously designed protocol that end points such as exercise capacity and symptoms could be improved. 4 Mortality was not assessed in this study, and only in a post hoc analysis was a favourable effect recognised. Subsequently, improved survival with ACE inhibitor therapy has been documented in patients with mild, moderate, and severe heart failure, such as in the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) and Studies Of Left Ventricular Dysfunction (SOLVD) treatment trials. 5, 6 ACE inhibitors were found also to prevent the onset of heart failure in patients with chronic asymptomatic left-ventricular dysfunction and in those with decreased ejection fractions after infarction. In the latter group, as well as in patients already with heart failure after infarction, survival was improved. Importantly, the Vasodilator-Heart Failure Trial (V-HeFT)-II found that treatment with an ACE inhibitor was associated with a better prognosis than a hydrallazine-nitrate and direct-acting vasodilator combination. 7, 8 Mechanism of Action ACE acts on angiotensin I (Ang I) to form angiotensin II (Ang II). Ang II acts on Ang II type 1 receptors located in numerous sites, including vascular smooth muscle, adrenal cortex, kidney and brain, and is consequently a key regulator of blood pressure and extracellular volume. Other angiotensin II receptor subtypes have been identified, and their influence on cardiovascular function is currently being studied. Ang II-mediated vasoconstriction of the efferent arterioles and increased adrenaline release from the adrenal medulla both contribute to elevating blood pressure, whilst it controls intravascular volume by promoting the synthesis and release of aldosterone from the adrenal cortex, which increases proximal tubular sodium reabsorption. Other effects include thirst stimulation, decreased renin secretion, increased antidiuretic hormone secretion from the central nervous system, and mitogenesis of cardiac and vascular muscle cells.
ACE inhibitors inhibit the production of Ang II and increase concentrations of the vasodilator bradykinin by inhibiting its degradation. Bradykinin has beneficial effects associated with the release of nitric oxide and prostacyclin, which may contribute to the positive haemodynamic effects of the ACE inhibitors. Bradykinin may also be responsible, however, for some of the adverse effects, such as dry cough, hypotension, and angio-oedema. ACE inhibitors also reduce the activity of the sympathetic nervous system as Ang II promotes the release of noradrenaline and inhibits its reuptake. In addition, they increase beta-receptor density and improve variation in heart rate, baroreceptor function and autonomic function (including vagal tone).
Although ACE inhibitors were first used for their antihypertensive effect, several well-designed clinical trials in the last two decades have established their benefit in cardiovascular risk reduction. ACE inhibition may have a beneficial effect on fibrinolytic balance by inhibiting the formation of Ang II, which is thought to be prothrombotic, and by promoting an antithrombotic effect through bradykinin accumulation. Another theory suggests that ACE inhibitors that act on vascular endothelium, specifically on the endothelial B2 kinin receptors, may interfere with signalling of these receptors and enhance the vascular response to bradykinin. Experimental data using the ACE inhibitor ramiprilat, the active diacid metabolite of ramipril, provide evidence in support of this theory. 9 However, further research is needed to confirm this benefit and to determine whether differences in the degree of tissue activity among ACE inhibitors influence vascular response. ACE inhibitors have also been shown to inhibit cellular proliferation, decrease apoptosis and inhibit fibrosis in the vasculature, heart and kidneys, as well as preserving renal function. In a post hoc analysis of the Ramipril Efficacy in Nephropathy study, ramipril reduced the rate of glomerular filtration rate decline and the incidence of endstage renal disease. 10 Recent studies on animal models have also suggested that at least some of the beneficial effects of ACE inhibitors, including imidapril, on heart failure may be due to changes in the sarcolemmal Na + -K + -ATPase. 11
Review
Imidapril is a carboxylic acid prodrug that undergoes hydrolysis in the liver to form its active metabolite imidaprilat. The main pharmacokinetic properties of imidapril are shown in Table 1 .
Absorption
Studies with radio-labelled imidapril showed that approximately 40% of the drug is absorbed after oral administration. 12 In a randomised, doubleblind, placebo-controlled trial in 91 patients with mild-to-moderate essential hypertension, imidapril 5, 10 and 20 mg demonstrated maximal reduction in sitting diastolic blood pressure five to six hours after administration of the first dose. Maximal ACE inhibition occurred four to eight hours after single dose administration, with a 65% to 80% reduction in ACE activity. 13 
Distribution
In an open, non-randomised trial in 10 hypertensive patients, imidaprilat plasma concentrations of approximately 5 ng/mL were required to produce maximal reduction in blood pressure, as well as maximal ACE activity inhibition. Imidapril and imidaprilat peak concentrations ranged from 29 to 49 ng/mL and 6 to 26 ng/mL, respectively, after a single 10 mg dose, and 22 to 47 ng/mL and 15 to 26 ng/mL, respectively, after four weeks of treatment. At steady-state, the average trough concentration was 4 ng/mL, which is adequate to provide 24hour coverage with once-daily dosing.
A trial in healthy volunteers found maximal ACE inhibition occurred with imidaprilat plasma levels above 10 ng/mL 12 . Peak concentrations of imidapril and imidaprilat ranged from 24 to 44 ng/mL and 7 to 17 ng/mL, respectively, after a single 10 mg dose, and 25 to 66 ng/mL and 6 to 29 ng/mL, respectively, after approximately one week of therapy. At steady state, following eight days of imidapril 10 mg once-daily, trough concentrations ranged from 2.5 to 4.7 ng/mL.
Metabolism
Imidapril, a prodrug, is rapidly converted to the active drug via hydrolysis of the ethylester moiety, leading to formation of the diacid imidaprilat. 14
Excretion
Following hydroxylation in the liver, imidapril is eliminated renally. Renal excretion of imidapril and imidaprilat in eight healthy volunteers was 6.5% to 18% and 2.4% to 10%, respectively, after a single 10 mg dose, and 6% to 14% and 4% to 22%, respectively, after seven days of therapy. 15 In eight healthy volunteers given imidapril 10 mg once-daily for seven days, the elimination half-life of imidapril ranged from 1.1 to 2.5 hours and that of imidaprilat from 10.1 to 14.7 hours; others have reported values of 18 to 19 hours for the half-life of imidaprilat. [14] [15] [16] 
Special Populations
The pharmacokinetics of imidapril and imidaprilat have been determined in patients with liver disease, impaired renal function and mild-to-moderate hypertension.
The disposition of imidapril and imidaprilat in patients with chronic renal failure was studied by Hoogkamer et al. 14 Twenty-four volunteers were divided into three groups according to their renal function: group 1 consisted of eight healthy individuals (mean age 53 years) with normal renal function (mean creatinine clearance 116 ml/min) and the remaining 16 subjects (mean age 58 years) were equally distributed into group 2 (mean creatinine clearance 64 ml/min) and group 3 (mean creatinine clearance 18 ml/min). Following a single oral dose of imidapril 10 mg, the maximum plasma concentration (C max ) and area under the curve (AUC)∞ of imidapril in group 3 were three-fold greater than those in the group with normal renal function (p<0.05), whilst the C max and AUC∞ of imidaprilat were six-and 12-fold greater, respectively (p<0.05). After seven once-daily doses of imidapril 10 mg, the differences in the C max and AUC∞ of imidapril between groups 1 and 3 were similar to those seen after a single dose, whilst the C max and AUC∞ of imidaprilat in group 3 were three-four-fold and six-fold greater, respectively, than the corresponding group 1 parameters (p<0.05). The authors concluded that minimum clinically effective doses should be given to patients with a creatinine clearance of <25 ml/min. 16 Eight subjects (mean age 43 years) had normal liver function and eight subjects (mean age 55 years) had impaired liver function (fatty liver disease in six cases and grade A Child-Pugh classification cirrhosis in two cases). There were no significant differences in C max , time to maximum plasma concentration, AUC or plasma beta-half-life between the two groups after one or seven doses, with the exception of imidaprilat C max on day 1, which was two-fold lower in the subjects with impaired hepatic function (p<0.05). Hence, Hoogkamer and associates concluded that patients with hepatic disease do not require dosage modification of imidapril.
Drug Interactions Aspirin
Aspirin inhibits the production of prostaglandins, including vasodilator and anti-thrombotic prostaglandins. The production of vasodilator prostaglandins may be an important counterregulatory pathway in patients with heart failure. Ang II can stimulate the production of vasodilator prostaglandins, and the use of ACE inhibitors could theoretically reduce renal prostaglandin synthesis. However, the overall effect of ACE inhibitors on prostaglandin synthesis and platelet aggregability remains controversial, and the data on the interaction between aspirin and ACE inhibitors is inconclusive. 17
Nonsteroidal Anti-inflammatory Drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) can decrease the antihypertensive and natriuretic effect of ACE inhibitors, particularly in low renin hypertensive patients. 18 The mechanism may involve interference with the production of vasodilator and natriuretic prostaglandins that are stimulated by antihypertensive agents. While there are no known significant pharmacokinetic interactions between NSAIDs and ACE inhibitors, their combination can result in side effects such as marked bradycardia due to hyperkalaemia and this can further lead to syncope. Aged patients suffering from hypertension, diabetes mellitus, ischaemic heart disease or degenerative joint disease must be careful when taking these medications in combination.
Potassium ACE inhibitors lower aldosterone levels which, in turn, can result in potassium retention. There have been case reports of severe hyperkalaemia and arrhythmias due to ingestion of potassium supplements in conjunction with ACE inhibitor therapy. 18, 19 In patients with renal dysfunction or in those receiving potassium supplements, the increase in serum potassium is usually evident within two to four days.
Potassium-sparing Diuretics
Concurrent use of potassium-sparing diuretics (spironolactone, canrenoate potassium, amiloride, triamterene) and an ACE inhibitor has been reported to increase serum potassium by 1 to 1.5 mEq/L when compared with either drug used alone. This has occasionally resulted in significant arrhythmias and very rarely death. 20 21, 22 Imidapril is as effective as nifedipine in reducing left ventricular hypertrophy in hypertensive patients. 23 Symptomatic Left Ventricular Dysfunction ACE inhibitors, when added to diuretics, improve symptoms, exercise tolerance and survival, and reduce hospital admission rates, in patients with chronic heart failure. These beneficial effects are apparent in all grades of systolic heart failure. This has been demonstrated for mild-to-moderate chronic heart failure by, for example, the Munich Mild Heart Failure Trial, 24 the V-HeFT 4 and the SOLVD-treatment 5 studies, and for severe chronic heart failure by the CONSENSUS. 6 Asymptomatic Left Ventricular Dysfunction ACE inhibitors have also been shown to be effective in asymptomatic left ventricular dysfunction. For example, in the SOLVDprevention trial, enalapril reduced the incidence of heart failure and related hospital admissions in patients with asymptomatic left ventricular systolic dysfunction. 25 
Efficacy

ACE Inhibitors
Left Ventricular Dysfunction after Myocardial Infarction
Large scale, randomised controlled trials, such as the Acute Infarction Ramipril Efficacy (AIRE) study, 26 the Survival And Ventricular Enlargement (SAVE) study, 27 and the Trandolapril Cardiac Evaluation (TRACE) study, 28 Slowing Disease Progression ACE inhibitors also seem to influence the natural course of chronic heart failure. The Munich Mild Heart Failure Trial showed that ACE inhibitors combined with standard treatment slowed the progression of heart failure in patients with mild symptoms, with significantly fewer patients developing severe heart failure than in the placebo group. 24
Imidapril
Dose-finding Trial
In a double-blind, randomised, dose-finding trial in 24 patients with stable chronic heart failure (New York Heart Association [NYHA] functional class II-III), imidapril 2.5 and 5 mg once-daily significantly (p<0.05) decreased systolic blood pressure, although diastolic blood pressure was significantly (p<0.05) reduced only by the 5 mg/day dose. 29 Both doses significantly (p<0.05) suppressed ACE activity (Figure 1 ).
Pivotal Trial in Chronic Heart Failure
Following the dose-finding trial, a large-scale pivotal study was conducted to compare three doses of imidapril (2.5, 5 and 10 mg/day). 30 This randomised, double-blind, placebo-controlled, parallel-group trial was conducted in 244 patients with mild-to-moderate chronic heart failure (NYHA class II-III: approximately 80%/20%) who were stable on digoxin and diuretics. Patients were treated for 12 weeks and the main end points were exercise capacity and plasma neurohormone levels. The four treatment groups were well-matched with regard to demographic variables at baseline ( Table 2) .
A total of 25 patients dropped out of the study prematurely. Of these 25, three died and nine developed progressive chronic heart failure, which was significantly less common with imidapril than with placebo (3/182 patients on imidapril vs. 6/62 patients on placebo; p<0.05). Exercise time increased by 45 seconds in the 10 mg imidapril group (p=0.02 vs. placebo), but it did not change significantly in the 5 mg (16 seconds) or 2.5 mg (11 seconds) groups compared with placebo (3 seconds) ( Figure 2 ). Physical working capacity also increased in a dose-related manner.
Plasma levels of brain natriuretic peptide and atrial natriuretic peptide decreased in the imidapril groups (p<0.05 for linear trend), while adrenaline, noradrenaline, aldosterone and endothelin were not significantly affected. Renin increased in a dose-related manner, but plasma ACE activity was suppressed to a similar extent The results of this study show that, already within three months of treatment initiation, high-dose ACE inhibition with imidapril is superior to low-dose therapy. This is reflected by a more pronounced effect on exercise capacity and some neurohormone levels, but it does not appear to be related to the extent of suppression of plasma ACE.
Heart Failure due to Idiopathic Dilated Cardiomyopathy
Eighteen patients (mean age 58 years) with moderate chronic heart failure secondary to idiopathic dilated cardiomyopathy (mean ejection fraction 33%) were studied to clarify whether ACE inhibitor treatment improves excess ventilation during exercise. 31 Treatment with imidapril 5 mg/day or enalapril 5 mg/day for one week had a beneficial effect on excess ventilation during exercise, without a significant improvement in exercise capacity.
Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction
The purpose of this study was to compare the effects of imidapril and bisoprolol on left ventricular remodelling after acute MI. 32 Sixty patients who underwent re-perfusion therapy were randomly assigned to imidapril (20 patients), bisoprolol (20 patients) or a control group (20 patients) . Administration was started within 24 hours of MI. Left ventricular function was assessed on admission and after three months and one year.
Baseline characteristics were similar in all three groups except for sex distribution. Compared with the imidapril group, patients treated with bisoprolol had a significantly (p<0.01) higher mean pulmonary capillary wedge pressure (12 + 7 mmHg vs. 8 + 2 mmHg) and left ventricular end-diastolic pressure (17 + 8 mmHg vs. 11 + 4 mmHg) after one year. Left ventricular enddiastolic volume index increased significantly (p<0.01) in the bisoprolol group throughout the one-year period, whereas a significant (p<0.01) decrease was seen in the imidapril group. The increase in the bisoprolol group (12 + 10 mL/m 2 ) was significantly (p<0.01) greater than that in the imidapril group (-9 + 7 mL/m 2 ) and the control group (4 + 11 mL/m 2 ). The authors concluded that early treatment with bisoprolol in patients with acute MI cannot prevent left ventricular remodelling, whereas imidapril attenuates left ventricular dilation by decreasing the preload.
Renal Effects
In a study in patients with diabetic nephropathy, no significant difference in serum creatinine levels was observed between the imidapril and placebo groups, and urinary albumin excretion was significantly reduced by imidapril while captopril hardly reduced UAE. 33
Response to Imidapril and Genetic Polymorphism
Although at an early stage, there are recent suggestions that genetic polymorphisms may affect patient responses to imidapril. Although there are, as yet no studies in patients suffering from heart failure, a study in 105 hypertensive Japanese patients indicates that a single nucleotide polymorphism at position -816 of the carboxylesterase 1 (CES1) gene (which is responsible for the enzyme which activates imidapril) can determine responsiveness to imidapril. 34 Similarly, a larger study in 509 hypertensive patients suggests that -344C/T polymorphism of the aldosterone synthase gene may be an important determinant of the response to imidapril and other ACE inhibitors. 35
Overview of Safety and Tolerability Hypertensive Patients
In a 12-week, double-blind, parallel-group study, 57 patients with mild-to-moderate hypertension were randomly allocated to imidapril (5 mg once daily) or captopril (25 mg twice daily). 36 Cough is one of the most common side-effects encountered with the ACE inhibitors. A comparative crossover study was therefore conducted to compare the incidence of cough between the two ACE inhibitors, imidapril and enalapril. 37 A total of 489 patients with essential or renal parenchymal hypertension were randomly assigned to one of two treatment groups: one received imidapril for 12 weeks (Period I) followed by enalapril for 12 weeks (Period II), whilst in the other group, the order of the drugs was reversed. The occurrence of cough during treatment was monitored by questionnaire. There were no differences in background characteristics between the two groups. The incidence of cough during Period I was 15.2% (32/210) in the group initially treated with imidapril and 38.6% (85/220) in the group initially treated with enalapril, the difference being statistically significant (p<0.001). The cough disappeared in approximately half of the patients who developed a cough with enalapril during Period I and who were subsequently switched to imidapril. During Period I, a reduction in blood pressure was observed in 63.9% of patients given imidapril and 64.6% of those given enalapril. It was concluded that the incidence of cough was significantly less under imidapril than under enalapril treatment, while there was no difference in the antihypertensive effects of the two ACE inhibitors.
Heart Failure Patients
No serious adverse effects were observed in the dose-finding study involving 24 patients treated with imidapril 2.5 or 5 mg/day, although symptomatic hypotension occurred in one patient given 5 mg/day. The decrease in blood pressure was not related to baseline ACE activity, serum sodium or serum creatinine concentration.
In the pivotal double-blind, placebo-controlled trial of imidapril (2.5, 5 and 10 mg/day) conducted in 244 patients with mild-to-moderate chronic heart failure, four patients discontinued the study due to side effects (Table 4 ), including one with dry cough, and one with angioedema. No other significant side effects were reported, and there were no significant biochemical or haematological changes.
Conclusions
ACE inhibitors improve the prognosis in mild, moderate and severe heart failure, as well as in heart failure due to MI, and even in asymptomatic patients. Imidapril is a long-acting, non-sulfhydryl ACE inhibitor, which has been used clinically in the treatment of hypertension, chronic heart failure, acute MI and diabetic nephropathy. It may be associated with a lower incidence of dry cough than some other ACE inhibitors.
After oral administration, imidapril is rapidly converted in the liver to its active metabolite imidaprilat. In vitro studies show imidapril and its metabolite imidaprilat to be at least three times more potent than enalapril, enalaprilat and captopril. 38 The plasma level of imidaprilat gradually increases in proportion to the dose, and declines slowly. The time to reach maximum plasma concentration is two hours for imidapril and around 5-6 hours for imidaprilat, whilst the corresponding elimination half-lives are 1.1-2.5 and 10-19 hours, respectively. In patients with hypertension, blood pressure remains decreased 24 hours after imidapril administration. Good tissue penetration and inhibition of tissue ACE by imidapril contributes to its effectiveness in preventing cardiovascular complications of hypertension.
In patients with mild-to-moderate chronic heart failure, imidapril 10 mg once-daily significantly increased exercise time and physical working capacity, reduced blood pressure and decreased plasma atrial natriuretic peptide and brain natriuretic peptide levels. When given to patients with acute MI, imidapril improved left ventricular ejection fraction and was significantly more effective than bisoprolol.
Definitive conclusions regarding the relative efficacy, safety and tolerability of this agent compared with other ACE inhibitors is not possible, but imidapril seems to be associated with a considerably lower incidence of cough than captopril and enalapril. 39 In conclusion, imidapril is a versatile ACE inhibitor that has been well investigated and proved to be safe and effective. There is longterm practical experience with imidapril in the treatment of hypertension and sufficient evidence in the therapy of chronic heart failure to confirm its benefits. The major advantages of imidapril are its activity in the treatment of a range of cardiovascular diseases, such as congestive heart failure, associated with the lower incidence of cough compared with some of the older ACE inhibitors. 
Review
